SLXN · Silexion Therapeutics Corp · Metrics
$1.37
-0.14 (-9.00%)
At close · Nov 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of September 30, 2026, we had cash and cash equivalents of $4.8 million. Based on our current cash balance, as well as our history of operating losses and negative cash flows from operations, combined with our anticipated use of cash to, among other things, (i) fund the clinical development of SIL204, (ii) identify and develop new product candidates, and (iii) seek approval for SIL204 and any other product candidates we may develop, our management has concluded that we do not have sufficient cash to fund our operations for 12 months from the issuance date of our consolidated financial statements for the three-month and nine-month periods ended September 30, 2026 included in this quarterly report, but rather, for only several months from the filing date of this quarterly report, under our current business plan, as a result, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 12, 2026
Market Cap
$974,292
Shares
649,528
Volume · Nov 20
8207
Avg daily vol (7 sessions)
84.05K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
SLXN metrics
47 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$1.50
Market cap
$974,292
Price action
23 metricsPrice change (1W)
-43.6%
Price change (30D)
-53.6%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
$760.08
52-week low
$1.44
Change from 52-week high
-99.8%
Change from 52-week low
+4.2%
Annualized volatility
—
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
649,528
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.3
reciprocal yield 304.6%
FCF yield
-1,205.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,357.8%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$13.52M
Net income (TTM)
−$13.23M
Trailing 12 months
Diluted EPS (TTM)
$-157.12
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
-98.0%
Shares change YoY
+3,817.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-445.7%
Return on assets
-193.8%
Debt / equity
—
Current ratio
1.7
EBITDA (TTM)
—
Free cash flow (TTM)
−$11.74M
Quick ratio
1.7
Interest coverage
-6,759.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$4.76M
Latest balance sheet
Cash & equivalents
$4.76M
Total assets
$6.83M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$11.70M
Capital expenditures (TTM)
$44,000
R&D (TTM)
$8.24M
SG&A (TTM)
—
Stock compensation (TTM)
$596,000
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
11
13F filer change QoQ
+4
Institutional ownership
26.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
10.7%
Private-fund adviser ownership
9.4%
Active holders' share change QoQ
+4,789.3%
Holder tenure
1.2
Price vs estimated holder cost
-77.6%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.0%
Short interest
3 metricsShort interest
0.5%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
41 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged
Key facts
CIK
2022416
CUSIP
G1281K148
13F (30d)
13 filings
11 filers
Visit website
Investor relations